Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
51.56
-0.48 (-0.92%)
Nov 12, 2026, 4:00 PM EST - Market closed
Travere Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 651.03 | 490.73 | 233.18 | 145.24 | 109.46 | 131.84 | |
Revenue Growth | 49.38% | 110.45% | 60.55% | 32.69% | -16.97% | -33.52% |
Cost of Revenue | 253.47 | 216.35 | 225.24 | 256.44 | 231.75 | 204.98 |
Gross Profit | 397.56 | 274.38 | 7.94 | -111.2 | -122.29 | -73.14 |
Selling, General & Admin | 417.94 | 337.2 | 264.12 | 265.54 | 197.52 | 126.28 |
Operating Expenses | 417.94 | 337.2 | 264.12 | 265.54 | 197.52 | 126.28 |
Operating Income | -20.38 | -62.82 | -256.18 | -376.74 | -319.81 | -199.43 |
Interest Expense | -8.87 | -10.75 | -11.18 | -11.33 | -11.01 | -19.68 |
Interest & Investment Income | 12.24 | 12.72 | 17.82 | 21.77 | 6.28 | 1.99 |
Earnings From Equity Investments | - | - | -3.4 | - | - | - |
Currency Exchange Gain (Loss) | -0.3 | -0.3 | -0.7 | 0.5 | 1.4 | 0.3 |
Other Non Operating Income (Expenses) | -29.3 | 11.87 | 0.78 | 1.09 | -0.43 | -0.07 |
EBT Excluding Unusual Items | -46.62 | -49.28 | -252.87 | -364.72 | -323.58 | -216.88 |
Merger & Restructuring Charges | - | - | -2.44 | -11.39 | - | - |
Gain (Loss) on Sale of Investments | 0.01 | 0.01 | - | - | - | - |
Other Unusual Items | - | - | - | - | -7.58 | - |
Pretax Income | -159.72 | -49.27 | -320.51 | -376.11 | -331.16 | -216.88 |
Income Tax Expense | -5.3 | 0.99 | 0.12 | 0.22 | 0.31 | 0.41 |
Earnings From Continuing Operations | -154.42 | -50.26 | -320.63 | -376.33 | -331.47 | -217.29 |
Earnings From Discontinued Operations | 32.92 | 24.72 | -0.92 | 264.93 | 52.99 | 37.2 |
Net Income | -121.51 | -25.55 | -321.55 | -111.4 | -278.48 | -180.09 |
Net Income to Common | -121.51 | -25.55 | -321.55 | -111.4 | -278.48 | -180.09 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 93 | 89 | 79 | 74 | 64 | 60 |
Shares Outstanding (Diluted) | 93 | 89 | 79 | 74 | 64 | 60 |
Shares Change | 5.90% | 13.08% | 6.22% | 16.48% | 6.56% | 25.86% |
EPS (Basic) | -1.31 | -0.29 | -4.08 | -1.50 | -4.37 | -3.01 |
EPS (Diluted) | -1.31 | -0.29 | -4.08 | -1.50 | -4.37 | -3.01 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 176.96 | 37.78 | -237.48 | -280.02 | -186.29 | -19.89 |
Free Cash Flow Per Share | 1.91 | 0.42 | -3.01 | -3.77 | -2.92 | -0.33 |
Gross Margin | 61.07% | 55.91% | 3.40% | -76.57% | -111.72% | -55.48% |
Operating Margin | -3.13% | -12.80% | -109.87% | -259.40% | -292.17% | -151.27% |
Profit Margin | -18.66% | -5.21% | -137.90% | -76.70% | -254.41% | -136.60% |
Free Cash Flow Margin | 27.18% | 7.70% | -101.84% | -192.80% | -170.19% | -15.09% |
EBITDA | 32.4 | -2.08 | -212.63 | -338.21 | -299.09 | -186.68 |
EBITDA Margin | 4.98% | -0.42% | -91.19% | -232.87% | -273.25% | -141.60% |
D&A For EBITDA | 52.78 | 60.74 | 43.56 | 38.53 | 20.72 | 12.75 |
EBIT | -20.38 | -62.82 | -256.18 | -376.74 | -319.81 | -199.43 |
EBIT Margin | -3.13% | -12.80% | -109.87% | -259.40% | -292.17% | -151.27% |
Revenue as Reported | 651.03 | 490.73 | 233.18 | 145.24 | 109.46 | 131.84 |